Print
March 8, 2010
ADVAXIS CONFIRMS LONG-TERM STABILITY OF LISTERIA-BASED IMMUNOTHERAPEUTICS' FORMULATIONS
GMP Practices Potentially Viable for Commercialization Protocol
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.
Advaxis has developed and validated novel production methods for the bacterial cancer vaccine currently in clinical trials. The original good manufacturing practice (GMP) batch of the Company’s Listeria-based immunotherapeutic which has been kept in a frozen state has been tested and found to be stable and to still meet release specifications approximately four years and nine months after manufacture.
“The ability to make a reproducible live Listeria vaccine with long-term storage stability is an essential part of the commercial development process,” commented Advaxis Chairman/CEO Thomas A. Moore. “As we continue to refine our FDA-approved production methods, further research may produce substantive improvements.”
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.
For further information, please visit the Company’s portals on the following sites: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.